Impact of pre-existing drug resistance on risk of virological failure in South Africa.

ABSTRACT:

Objectives

There is conflicting evidence on the impact of pre-existing HIV drug resistance mutations (DRMs) in patients infected with non-B subtype virus.

Methods

We performed a case-cohort substudy of the AIDS Drug Resistance Surveillance Study, which enrolled South African patients initiating first-line efavirenz/emtricitabine/tenofovir. Pre-ART DRMs were detected by Illumina sequencing of HIV pol and DRMs present at <20% of the viral population were labelled as minority variants (MVs). Weighted Cox proportional hazards models estimated the association between pre-ART DRMs and risk of virological failure (VF), defined as confirmed HIV-1 RNA ≥1000 copies/mL after ≥5 months of ART.

Results

The evaluable population included 178 participants from a randomly selected sub

SUBMITTER: Li JZ 

PROVIDER: S-EPMC8599859 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature